Business Valuation Zone

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

companies allergan-plc

Allergan Fined for Failure to Disclose Merger Negotiations with Third Parties During Hostile Bid

Cooley M&A

JANUARY 24, 2017

Specifically, the SEC said Allergan failed to disclose negotiations with a merger party (Company A) that it wanted to acquire to make it more difficult for Valeant/Pershing Square to finance a hostile takeover of Allergan as a much-larger combined company.

Finance

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology

Benzinga

DECEMBER 13, 2022

–Robert Palmisano of Priveterra to become chairman of the Board of Directors; combined company to be led by AEON CEO Marc Forth –. Transaction values the combined company at a post-money equity value of $475.5M Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. IRVINE, Calif.,

Marketability

Marketability Equity

Allergan Fined for Failure to Disclose Merger Negotiations with Third Parties During Hostile Bid

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology

Stay Connected